{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:15:14Z","timestamp":1791494114132,"version":"4.3.4"},"reference-count":80,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Renin\u2013angiotensin\u2013aldosterone system (RAAS) inhibitors are standard care in patients with hypertension, heart failure or chronic kidney disease (CKD). Although we have studied the RAAS for decades, there are still circumstances that remain unclear. In this review, we describe the evolution of the RAAS and pose the question of whether this survival trait is still necessary to humankind in the present age. We elucidate the benefits on cardiovascular health and kidney disease of RAAS inhibition and present promising novel medications. Furthermore, we address why more studies are needed to establish a new standard of care away from generally prescribing ACEi or ARB toward an improved approach to combine drugs tailored to the needs of individual patients.<\/jats:p>","DOI":"10.3390\/ijms25074035","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T10:42:03Z","timestamp":1712227323000},"page":"4035","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Renin\u2013Angiotensin\u2013Aldosterone System: From History to Practice of a Secular Topic"],"prefix":"10.3390","volume":"25","author":[{"given":"Sara H.","family":"Ksiazek","sequence":"first","affiliation":[{"name":"6th Medical Department of Internal Medicine with Nephrology & Dialysis, Clinic Ottakring, 1160 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilio","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy"},{"name":"Nephrology, Dialysis and Renal Transplant Unit, IRCCS Azienza Ospedaliero, Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"And\u00f2","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"},{"name":"Centro Sanitario, Via P. Bucci, University of Calabria, 87036 Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1211-0253","authenticated-orcid":false,"given":"Markus","family":"Pirklbauer","sequence":"additional","affiliation":[{"name":"Internal Medicine IV, Medical University Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus D.","family":"S\u00e4emann","sequence":"additional","affiliation":[{"name":"6th Medical Department of Internal Medicine with Nephrology & Dialysis, Clinic Ottakring, 1160 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ruotolo","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Zaza","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"La Manna","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy"},{"name":"Nephrology, Dialysis and Renal Transplant Unit, IRCCS Azienza Ospedaliero, Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8532-0182","authenticated-orcid":false,"given":"Luca","family":"De Nicola","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Mayer","sequence":"additional","affiliation":[{"name":"Internal Medicine IV, Medical University Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2168-702X","authenticated-orcid":false,"given":"Michele","family":"Provenzano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"ref_1","unstructured":"Fountain, J.H., Kaur, J., and Lappin, S.L. (2023). StatPearls, StatPearls Publishing."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00000441-200307000-00003","article-title":"The Renin-Angiotensin-Aldosterone System: Cardiorenal Effects and Implications for Renal and Cardiovascular Disease States","volume":"326","author":"Brewster","year":"2003","journal-title":"Am. J. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Durango, N., Fuentes, C.A., Castillo, A.E., Gonz\u00e1lez-G\u00f3mez, L.M., Vecchiola, A., Fardella, C.E., and Kalergis, A.M. (2016). Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17070797"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"ii38","DOI":"10.1093\/ndt\/gfaa013","article-title":"Time for Clinical Decision Support Systems Tailoring Individual Patient Therapy to Improve Renal and Cardiovascular Outcomes in Diabetes and Nephropathy","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Provenzano, M., Maritati, F., Abenavoli, C., Bini, C., Corradetti, V., La Manna, G., and Comai, G. (2022). Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105719"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejim.2023.06.008","article-title":"Future Treatments in Hypertension: Can We Meet the Unmet Needs of Patients?","volume":"115","author":"Kanbay","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40656-022-00485-z","article-title":"Natural Selection According to Darwin: Cause or Effect?","volume":"44","author":"Bradley","year":"2022","journal-title":"Hist. Philos. Life Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/080370598437411","article-title":"LENNART The Renin-Angiotensin System\u2014A Century of Progress","volume":"7","author":"Hansson","year":"1998","journal-title":"Blood Press."},{"key":"ref_12","first-page":"1776","article-title":"Comparative Physiology of the Renin-Angiotensin System","volume":"36","author":"Taylor","year":"1977","journal-title":"Fed. Proc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00109-012-0894-z","article-title":"Emergence and Evolution of the Renin\u2013Angiotensin\u2013Aldosterone System","volume":"90","author":"Fournier","year":"2012","journal-title":"J. Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1161\/01.HYP.0000255165.84684.9d","article-title":"Evolution and Hypertension","volume":"49","author":"Weder","year":"2007","journal-title":"Hypertension"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ekir.2016.08.003","article-title":"ISN Forefronts Symposium 2015: The Evolution of Hypertension\u2013Old Genes, New Concepts","volume":"1","author":"Mansley","year":"2016","journal-title":"Kidney Int. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/08998280.2001.11927784","article-title":"Facts and Ideas from Anywhere","volume":"Volume 14","author":"Roberts","year":"2001","journal-title":"Baylor University Medical Center Proceedings"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1590\/2175-8239-jbn-3661","article-title":"Inappropriate Activity of Local Renin-Angiotensin-Aldosterone System during High Salt Intake: Impact on the Cardio-Renal Axis","volume":"40","author":"Gonsalez","year":"2018","journal-title":"J. Bras. Nefrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1093\/eurheartj\/ehr194","article-title":"Nutrition in Cardiovascular Disease: Salt in Hypertension and Heart Failure","volume":"32","author":"He","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1086\/420793","article-title":"Natural Selection and Population History in the Human Angiotensinogen Gene (AGT): 736 Complete AGT Sequences in Chromosomes from around the World","volume":"74","author":"Nakajima","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0002-9343(80)90444-1","article-title":"Is the Renin System Necessary?","volume":"69","author":"Brunner","year":"1980","journal-title":"Am. J. Med."},{"key":"ref_21","unstructured":"Bakogiannis, C., Theofilogiannakos, E., Papadopoulos, C., Lazaridis, C., Bikakis, I., Tzikas, S., and Vassilikos, V. A Translational Approach to the Renin-Angiotensin-Aldosterone System in Heart Failure, Ann. Res. Hosp."},{"key":"ref_22","first-page":"269","article-title":"RAAS Inhibition and Mortality in Hypertension","volume":"2013","author":"Ferrari","year":"2013","journal-title":"Glob. Cardiol. Sci. Pr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension","volume":"116","author":"Roks","year":"2015","journal-title":"Circ. Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Gant, C.M., Oosterwijk, M.M., Binnenmars, S.H., Navis, G.J., Haverkate, H., Bakker, S.J.L., and Laverman, G.D. (2023). Use of Maximal Dosage Renin-Angiotensin-Aldosterone System Inhibitors in a Real Life Population of Complicated Type 2 Diabetes\u2014Contraindications and Opportunities. BMC Nephrol., 24.","DOI":"10.1186\/s12882-023-03205-2"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1161\/HYPERTENSIONAHA.107.089110","article-title":"Response to Evolution and Hypertension: Is the Renin System Necessary?","volume":"49","author":"Weder","year":"2007","journal-title":"Hypertension"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/cphy.c130040","article-title":"Classical Renin-Angiotensin System in Kidney Physiology","volume":"4","author":"Sparks","year":"2014","journal-title":"Compr. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0002-9343(99)80226-5","article-title":"The Beneficial Effect of Angiotensin-Converting Enzyme Inhibition with Captopril on Diabetic Nephropathy in Normotensive IDDM Patients with Microalbuminuria. North American Microalbuminuria Study Group","volume":"99","author":"Laffel","year":"1995","journal-title":"Am. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000). Effects of Ramipril on Cardiovascular and Microvascular Outcomes in People with Diabetes Mellitus: Results of the HOPE Study and MICRO-HOPE Substudy. Lancet, 355, 253\u2013259.","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2023.04.052","article-title":"Cardiovascular Outcomes in Patients with Diabetes and Kidney Disease: JACC Review Topic of the Week","volume":"82","author":"Morales","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ekir.2023.10.006","article-title":"Updates on New Therapies for Patients with Chronic Kidney Disease","volume":"9","author":"Tarun","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e029565","DOI":"10.1161\/JAHA.122.029565","article-title":"Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection","volume":"12","author":"Tsukamoto","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of Sacubitril\/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1002\/ehf2.13644","article-title":"ARNI versus ACEI\/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction","volume":"8","author":"She","year":"2021","journal-title":"ESC Heart Fail"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00392-022-02124-w","article-title":"Real-World Comparative Effectiveness of ARNI versus ACEi\/ARB in HF with Reduced or Mildly Reduced Ejection Fraction","volume":"112","author":"Fu","year":"2023","journal-title":"Clin. Res. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes by Sodium\u2013Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_44","unstructured":"Boehringer Ingelheim (2024, March 03). Randomised, Double-Blind, Placebo-Controlled and Parallel Dose Group Trial to Investigate Efficacy and Safety of Multiple Doses of Oral BI 690517 over 14 Weeks, Alone and in Combination with Empagliflozin, in Patients with Diabetic and Non-Diabetic Chronic Kidney Disease, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05182840."},{"key":"ref_45","unstructured":"Quantum Genomics, SA (2024, March 03). A Phase 3, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, over 12 Weeks in Difficult-to-Treat\/Resistant Hypertensive Subjects, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04277884."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiorenal Medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000528066","article-title":"Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease","volume":"9","author":"Liu","year":"2023","journal-title":"Kidney Dis."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2022). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int., 102, S1\u2013S127.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pooled Analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/ckj\/sfad139","article-title":"Mineralocorticoid Receptor Antagonist Use in Chronic Kidney Disease with Type 2 Diabetes: A Clinical Practice Document by the European Renal Best Practice (ERBP) Board of the European Renal Association (ERA)","volume":"16","author":"Sarafidis","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_53","unstructured":"Bayer (2024, March 03). A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of FInerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients with Non-Diabetic Chronic Kidney Disease, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02540993."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients with Essential Hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s10157-021-02075-y","article-title":"Efficacy and Safety of Esaxerenone (CS-3150) in Japanese Patients with Type 2 Diabetes and Macroalbuminuria: A Multicenter, Single-Arm, Open-Label Phase III Study","volume":"25","author":"Ito","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_56","unstructured":"KBP Biosciences (2024, March 03). A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects with Uncontrolled Hypertension and Moderate or Severe (Stage 3b\/4) CKD, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04968184."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/ajh\/hpad066","article-title":"Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study","volume":"36","author":"Bakris","year":"2023","journal-title":"Am. J. Hypertens."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41440-023-01188-z","article-title":"Inhibition of Aldosterone Synthase: Does This Offer Advantages Compared with the Blockade of Mineralocorticoid Receptors?","volume":"46","author":"Ando","year":"2023","journal-title":"Hypertens Res."},{"key":"ref_60","first-page":"e36184","article-title":"Aldosterone Synthase Inhibitors and Dietary Interventions: A Combined Novel Approach for Prevention and Treatment of Cardiovascular Disease","volume":"15","author":"Awosika","year":"2023","journal-title":"Cureus"},{"key":"ref_61","unstructured":"(2023, November 10). Positive Results for Boehringer\u2019s Aldosterone Synthase Inhibitor in CK. Available online: https:\/\/www.thepharmaletter.com\/article\/german-family-owned-pharma-major-boehringer-ingelheim-today-announced-promising-14-week-phase-ii-data-for-bi-690517."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2048004014522440","DOI":"10.1177\/2048004014522440","article-title":"Aldosterone Synthase Inhibitors in Hypertension: Current Status and Future Possibilities","volume":"3","author":"Hargovan","year":"2014","journal-title":"JRSM Cardiovasc. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.cjca.2023.06.013","article-title":"New Approaches Targeting the Renin-Angiotensin System: Inhibition of Brain Aminopeptidase A, ACE2 Ubiquitination, and Angiotensinogen","volume":"39","author":"Lazartigues","year":"2023","journal-title":"Can. J. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1161\/HYPERTENSIONAHA.122.18731","article-title":"Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease","volume":"79","author":"Ye","year":"2022","journal-title":"Hypertension"},{"key":"ref_65","unstructured":"(2023, November 25). Single Dose of Zilebesiran Safely and Effectively Lowered Blood Pressure for Six Months. Available online: https:\/\/newsroom.heart.org\/news\/single-dose-of-zilebesiran-safely-and-effectively-lowered-blood-pressure-for-six-months."},{"key":"ref_66","unstructured":"(2023, November 26). Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk. Available online: https:\/\/www.biospace.com\/article\/alnylam-presents-positive-results-from-the-kardia-1-phase-2-dose-ranging-study-of-zilebesiran-an-investigational-rnai-therapeutic-in-development-for-the-treatment-of-hypertension-in-patients-at-high-cardiovascular-risk\/."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrneph.2015.30","article-title":"New Data Do Not SUPPORT Triple RAAS Blockade","volume":"11","author":"Danser","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1161\/HYPERTENSIONAHA.107.088963","article-title":"Evolution and Hypertension: Is the Renin System Necessary?","volume":"49","author":"Gavras","year":"2007","journal-title":"Hypertension"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group (2023). Herrington, W.G.; Staplin, N.; Wanner, C.; Green, J.B.; Hauske, S.J.; Emberson, J.R.; Preiss, D.; Judge, P.; Mayne, K.J.; et al. Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/13543784.2021.1869720","article-title":"Selective Endothelin A Receptor Antagonism in Patients with Proteinuric Chronic Kidney Disease","volume":"30","author":"Provenzano","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and Safety of Aldosterone Synthase Inhibition with and without Empagliflozin for Chronic Kidney Disease: A Randomised, Controlled, Phase 2 Trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"ref_74","unstructured":"Alnylam Pharmaceuticals (2024, March 03). A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients with Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05103332."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1681\/ASN.2020050723","article-title":"Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial","volume":"31","author":"Oshima","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ekir.2018.12.001","article-title":"Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?","volume":"4","author":"Perco","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2337\/dc16-2202","article-title":"Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes","volume":"40","author":"Mayer","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Panza, S., Malivindi, R., Caruso, A., Russo, U., Giordano, F., Gy\u0151rffy, B., Gelsomino, L., De Amicis, F., Barone, I., and Conforti, F.L. (2021). Novel Insights into the Antagonistic Effects of Losartan against Angiotensin II\/AGTR1 Signaling in Glioblastoma Cells. Cancers, 13.","DOI":"10.3390\/cancers13184555"},{"key":"ref_79","first-page":"e40725","article-title":"Renin-Angiotensin System: Updated Understanding and Role in Physiological and Pathophysiological States","volume":"15","author":"Kanugula","year":"2023","journal-title":"Cureus"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fendo.2014.00113","article-title":"Clinical Relevance of Local Renin Angiotensin Systems","volume":"5","author":"Campbell","year":"2014","journal-title":"Front. Endocrinol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/7\/4035\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:23:32Z","timestamp":1760106212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/7\/4035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":80,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ijms25074035"],"URL":"https:\/\/doi.org\/10.3390\/ijms25074035","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]}}}